Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Receivables - Net (2020 - 2025)

Historic Receivables - Net for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $133.3 million.

  • Bioventus' Receivables - Net rose 683.18% to $133.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.3 million, marking a year-over-year increase of 683.18%. This contributed to the annual value of $130.3 million for FY2024, which is 255.81% up from last year.
  • Bioventus' Receivables - Net amounted to $133.3 million in Q3 2025, which was up 683.18% from $135.3 million recorded in Q2 2025.
  • Bioventus' Receivables - Net's 5-year high stood at $148.3 million during Q3 2022, with a 5-year trough of $93.3 million in Q2 2021.
  • For the 5-year period, Bioventus' Receivables - Net averaged around $126.3 million, with its median value being $127.0 million (2023).
  • In the last 5 years, Bioventus' Receivables - Net skyrocketed by 4118.31% in 2022 and then crashed by 1455.78% in 2023.
  • Bioventus' Receivables - Net (Quarter) stood at $128.4 million in 2021, then increased by 11.65% to $143.3 million in 2022, then fell by 11.38% to $127.0 million in 2023, then grew by 2.56% to $130.3 million in 2024, then increased by 2.31% to $133.3 million in 2025.
  • Its Receivables - Net was $133.3 million in Q3 2025, compared to $135.3 million in Q2 2025 and $120.9 million in Q1 2025.